Assess the Downregulation of HIV-1 When Raltegravir is Added to a Virologically Suppressed HAART Regimen
| Status: | Completed |
|---|---|
| Conditions: | HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | July 2008 |
| End Date: | February 2011 |
A Pilot Study to Assess the Downregulation of HIV-1 Associated Chronic Inflammation in Patients With Limited Immunologic Responses When Raltegravir is Added to a Virologically Suppressed HAART Regimen
The purpose of this study is to determine whether or not adding Raltegravir to a fully
suppressive antiretroviral regimen will assist in reducing HIV-1 associated chronic
inflammation and increase the t-lymphocyte memory cell pool.
suppressive antiretroviral regimen will assist in reducing HIV-1 associated chronic
inflammation and increase the t-lymphocyte memory cell pool.
Inclusion Criteria:
1. At least 18 years of age
2. HIV-positive by Western blot or viral load
3. Viral load < 400 copies/ml
4. CD4+ T-lymphocyte count less than 350 cells/mm3 or change in CD4+ T-lymphocyte count
< 100 cells/mm3 for at least one year on stable HAART with viral load < 400 copies/ml
for the same period of time
Exclusion Criteria:
1. CD4+ T-lymphocyte count greater than or equal to 350 cells/mm3 or rise in CD4+
T-lymphocyte count greater than or equal to 100 cells/mm3 within one year of study
entry
2. Viral load > 400 copies/ml
3. Allergy or resistance to raltegravir
We found this trial at
1
site
National Jewish Health National Jewish Health is known worldwide for treatment of patients with respiratory,...
Click here to add this to my saved trials
